Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
株式のランク #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
株価
$0.00023723
最終同期: 2024-08-26
時価総額
$1.41K
変化(1日)
111.67%
変化(1年)
0.00%
FR
取引 Pharnext S.A. (ALPHA)

カテゴリー

Pharnext S.A.(ALPHA)の利益
Dec 2023 時点の利益 TTM: $-31.69M
Pharnext S.A. の最新の財務報告によると、同社の現在の利益は $-31.69M です。2022 年には $-43.29M の利益を上げ、これは 2021 年の利益 $-38.48M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Pharnext S.A. の利益の推移(2013 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-31.69M 1.28%
2023 $-31.29M -27.73%
2022 $-43.29M 12.50%
2021 $-38.48M 30.75%
2020 $-29.43M -0.92%
2019 $-29.70M 21.26%
2018 $-24.50M -15.52%
2017 $-29.00M 29.32%
2016 $-22.42M 87.83%
2015 $-11.94M -8.06%
2014 $-12.98M 1.29%
2013 $-12.82M 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -16,747.05%
US
$1.95B -6,256.06%
NL
- -
CH
$3.01B -9,585.74%
BE
- -
KR